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Abstract
Background: Medication Overuse Headache (MOH) is a prevalent and disabling disorder resulting from the overuse
of analgesic drugs, triptans or other acute headache medications. In previous proteomic studies, several proteins
have been found at high concentrations in the urine of MOH patients and in the serum of rats with neuropathic
pain. The aim of this study was to compare the serum levels of lipocalin-type Prostaglandin D2 synthase (L-PGDS),
Vitamin D-binding protein (VDBP), apolipoprotein E (APOE) and apolipoprotein A1 (APOA1) in MOH patients and
healthy individuals, further exploring their relationship with cutaneous pain thresholds (CPTs) in the territories
innervated by the trigeminal nerve.
Methods: Sixty-nine MOH patients and 42 age- and sex-matched healthy volunteers were enrolled in the study.
Von Frey-like filaments were applied to the skin territories innervated by the trigeminal nerve, to determine the
CPTs. L-PGDS, VDBP, APOE and APOA1 were quantified in the serum by Enzyme-linked Immunosorbent Assay
(ELISA). Clinical and laboratory data were collected. Comparisons between MOH patients and healthy individuals
were performed using independent t test or χ2 test. To correlate serum proteins with CPTs, Pearson correlation
coefficient or Spearman’s rank correlation coefficient were used.
Results: CPTs were lower among MOH patients. L-PGDS, VDBP and APOE had significantly different serum
concentrations between groups (p < 0.01), but no correlation was found with CPTs. APOA1 serum concentrations
did not differ between patients and healthy individuals.
Conclusions: L-PGDS, VDBP and APOE had abnormal serum levels in MOH patients, confirming their alteration in
some conditions of chronic headache and neuropathic pain. However, they had no relationship with CPTs. The in-
depth study of serum proteins represents a promising approach for a better understanding of MOH, as well as the
detection of candidate biomarkers for chronic headache or the risks associated with overuse medications.
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Background
Chronic pain (CP) is a major health care problem. It af-
fects approximately 20% of the European population [1],
and gives considerable costs to the society, more than
heart diseases, cancer and diabetes put together [2]. CP
is a persistent and disabling pain over a long period,
starting from tissue injuries or inflammation, or from
lesions of the nervous system [3]. The maintenance of
pain often aggravates the patient’s symptoms, originating
the phenomenon of central sensitization, which mani-
fests itself as pain hypersensitivity, allodynia and hyper-
algesia [4, 5]. Currently, CP treatment has limited effect
because of poor understanding of the mechanisms that
lead to the initiation and maintenance; the complete
elimination of pain is rarely obtainable. Important rea-
sons for this failure are the high variability of CP mani-
festations, as well as the absence of distinctive and
measurable biological traits.
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Headaches are prevalent among chronic painful disor-
ders. It is estimated that up to 5% of the general popula-
tion suffers from chronic headache, defined as headache
occurrence ≥15 days per month [6]. Chronic forms differ
from the episodic forms not only in frequency, but also
in the lack of effectiveness of most therapies, more
medication overuse and lower quality of life [7]. The al-
most daily intake of acute headache medications can
paradoxically worsen the chronic symptoms, leading to a
secondary headache named medication-overuse head-
ache (MOH) [8]. MOH may complicate the majority of
primary headaches and it can be caused by several acute
headache medications, including migraine-specific (trip-
tans and ergotamine) and nonspecific (nonsteroidal anti-
inflammatory drugs or NSAIDs, paracetamol, opioids
and combinations of analgesics or mixture) drugs. Every
class of overused drugs may have a precise causative
role, but the repeated intake of the drug does not seem
enough to generate MOH. When the acute headache
medication is taken regularly for non-headache indica-
tions, people without a history of headache do not de-
velop MOH [9, 10]. Thus, the association between an
individual predisposition and the effects of the headache
medications are probably crucial in its outcome [11]. At
present, there are no recognisable pathological traits as-
sociated with MOH. The only proposed was cutaneous
allodynia (CA) [12], defined as pain resulting from an in-
nocuous stimulus to normal skin.
Recently, several urinary proteins have been found at
high levels in MOH patients [13, 14]. One of the most
interesting was lipocalin-type prostaglandin D2 synthase
(L-PGDS). The enzyme is responsible for the biosyn-
thesis of prostaglandin D2 (PGD2), the most abundant
prostanoid produced in the central nervous system
(CNS) [15]. PGD2 is involved in a variety of physio-
logical functions, such as sleep induction, body
temperature regulation, vasodilation and pain responses,
including allodynia [16–19]. Although the role of L-
PGDS is not completely defined, the entire prostaglandin
system has a central position in pain and central
sensitization, resulting in induction of hyperalgesia and
CA [20–25]. These findings have been deepened into an
animal model of neuropathic pain, revealing an in-
creased expression of L-PGDS as well. Several other pro-
teins were identified in the rat serum 5 weeks after the
chronic constriction of sciatic nerve, including Vitamin
D-binding protein (VDBP), apolipoprotein E (APOE)
and apolipoprotein A1 (APOA1) [26]. Nonetheless,
quantitative Polymerase Chain Reaction (qPCR) analysis
showed that their transcript levels were overexpressed in
the lumbar spinal cord (origin of sciatic nerve), and not
in the striatum (an unrelated brain region) [26].
Assuming that some pathophysiological processes may
be shared between MOH and neuropathic pain, the
primary objective of this study was to quantify and com-
pare the serum levels of L-PGDS, VDBP, APOE and
APOA1, as well as the cutaneous pain thresholds (CPTs)
in the territories innervated by the trigeminal nerve in
MOH patients and healthy individuals as control group.
Secondarily, serum levels of proteins have been corre-
lated with CPTs in MOH patients.
Methods
Population of the study
Between September 2016 and January 2018, 69 consecu-
tive MOH inpatients, referring to the Headache and
Drug Abuse Centre at the University of Modena and
Reggio Emilia, were enrolled in the study. All patients
were diagnosed by trained physicians, according to the
International criteria [8]. After signing written informed
consent, the collection of demographic data, the meas-
urement of blood pressure and experimental procedures
were completed on admittance, before withdrawal treat-
ment was initiated. Patients were tested in the morning,
before taking any therapy. A trained investigator per-
formed the CPT tests. The blood and urine routine la-
boratory tests were performed on the second day of
hospitalization, fasting from midnight. For each patient,
the subsequent parameters were analysed: (1) prevalent
acute headache medication used, classified in triptans,
NSAIDs and mixtures (2) daily drug intake (DDI), mean
number of acute headache medications consumed every
day; (3) years of chronification (CHR), time elapsed since
the beginning of chronic symptoms. Prevalent acute
headache medication used and DDI were referred to a 3-
month period before testing.
Forty-two age- and sex-matched healthy volunteers
were enrolled as controls. They were recruited from the
hospital’s medical staff and their relatives. On the experi-
mental day, they also performed blood tests for renal
function. Only healthy subjects without migraine and
any headache disorders were included in the study, ex-
cept for tension-type headache for no more than 3 days
per month. The daily intake of medicines and the as-
sumption of acute pain medications more than five
times in the last month or in the previous 48 h of the ex-
perimental procedures were considered exclusion cri-
teria for the study. For all study participants, exclusion
criteria were: headache on admittance to the centre, al-
tered results in routine laboratory tests, other non-
cephalic chronic painful conditions, and autoimmune,
hepatic, renal, oncological, cardiovascular, psychiatric or
neurological relevant pathologies.
Serum samples collection and storage
Venous blood was collected in vacutainer tubes and
allowed to clot at room temperature for 1 h. Serum was
obtained by centrifugation at 2000 x g for 10 min at 4 °C;
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a mixture of protease inhibitors (Sigma-Aldrich) was
added to prevent protein degradation and alteration.
Samples were divided into aliquots and stored at − 80 °C
until analysis.
ELISA test
Globally, 111 serum samples, which were comprised of 69
MOH patients and 42 healthy individuals, were analysed by
ELISA test. Especially, the expression level of the following
proteins was evaluated: L-PGDS (human Prostaglandin D
Synthase, Lipocalin-type, ELISA kit, BioVendor, Brno, CZ),
VDBP (human Vitamin D-binding protein, ELISA kit,
Cusabio Biotech, USA), APOE (human apolipoprotein E,
Apo-E, ELISA kit, Cusabio Biotech, USA) and APOA1 (hu-
man apolipoprotein A1, Apo-A1, ELISA kit, Cusabio Bio-
tech, USA). The assays were performed according to the
manufacturer’s protocols and instructions.
L-PGDS and APOA1 assays employ the quantitative
sandwich enzyme immunoassay technique, while the
VDBP and APOE kits use the competitive inhibition en-
zyme immunoassay method. Briefly, in the first case,
diluted serum samples, standards and blanks were dis-
pensed in the microplate wells containing immobilized
pre-coated specific antibody for L-PGDS and APOA1, re-
spectively. After 1 h incubation, a horseradish peroxidase
(HRP)-conjugated antibody specific for L-PGDS and
APOA1 was added in each well of the plate, which was in-
cubated further for 1 h. Following a wash to remove any
unbound reagent, a substrate solution was added and
allowed to react with HRP-conjugate. A blue colour pro-
portional to the amount of sample protein bound in the
initial step developed. The reaction was interrupted by an
acid solution, which lead to a yellow product. The absorb-
ance was measured at λ 450 nm in a microplate reader
(Multiscan FC, Thermo Scientific, USA). Protein concen-
trations were calculated from a standard curve generated
by the protein stock solution furnished with the kit.
VDBP and APOE kits used a microtiter plate pre-
coated with the respective proteins. Standards and sam-
ples (50 μL) were added to the plate wells, together with
the same amount of HRP-conjugated antibody specific
for the protein, and incubated at 37 °C. This step was
followed by aspiration and washing repeatedly for five
times before adding 90 μL of tetramethylbenzidine
(TMB) substrate solution to each well (in this case, the
colour developed in an opposite way to the amount of
protein present in the serum sample). After 10 min incu-
bation at 37 °C in the dark, the reaction was interrupted
by adding 50 μL of stop solution and the colour intensity
was measured within 5min at λ 450 nm.
Cutaneous pain thresholds
All the CPTs assessments were performed in absence of
a visible headache attack. Calibrated von Frey-like
filaments (Touch-Test® Sensory Evaluators filaments,
North-Coast Medical Inc., CA) were applied sequentially
in scheduled areas, in increasing order for 2 seach to de-
termine the basal CPTs, asking the patient when the
touch became a painful or very uncomfortable sting. As-
sessments were repeated three times and the filaments
were used in each location in the following sequence,
representing the increased strengths measured in grams
(e.g. 0.008; 0.02; 0.04; 0.07; 0.16; 0.4; 0.6; 1; 1.4; 2; 4; 6; 8;
10; 15; 26; 60; 100; 180 and 300 g). The test investigated
three cutaneous areas: temple, cheekbone and chin areas
(exploring first, second and third division of the trigemi-
nal nerve, respectively), assessed bilaterally in random
order. Landmarks definitions were: temple, the skin over
the pars orbitalis of frontal and sphenoid bones; cheek-
bone, the skin over periorbital area of zygomatic bone;
chin, the skin of the chin, including the innervation ter-
ritories of the lower alveolar nerves.
Statistical analysis
Quantitative variables were expressed as a mean ± stand-
ard deviation. Qualitative variables were expressed as a
percentage. Comparison of quantitative variables be-
tween MOH patients and healthy individuals was per-
formed using independent t test, whereas comparison of
qualitative variables was performed using χ2. All p-values
are two-sided, with a level of significance of 1%. To cor-
relate serum L-PGDS, VDBP, APOE and APOA1 with
CPTs, data were analysed with the Pearson correlation
coefficient or, if one of the two variables was not nor-
mally distributed, Spearman’s rank correlation coeffi-
cient was used. R software (version 3.4.3) was used to
perform statistical analysis. The level of significance for
correlation tests was set at 5%.
Results
Population characteristics
We enrolled 69 MOH patients, aged between 27 and 74
years (mean = 50.2), most of them were females. In more
than 90% of cases, the pre-existing headache disorder
was migraine. Tension-type headache was diagnosed as
pre-existing headache disorder in three patients, while
post-traumatic headache in one patient. On admittance,
headache was daily or almost daily for all patients, for
not less than 3 months. They assumed about two acute
headache medications a day (mean = 1.8, range = 0.33–
9), and had been suffering of more than 10 years of
chronic headache (mean = 12.1, range = 0.33–35). Ac-
cording to the prevalent use of acute headache medica-
tions, the majority assumed triptans (n = 48; 70%), fewer
patients were taking NSAIDs (n = 10; 14%) or mixture
drugs (n = 11; 16%). The latter consisted of a drug con-
taining indomethacin, caffeine and prochlorperazine in
90% of cases, the remaining ones were codeine plus
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paracetamol. Blood and urine laboratory tests showed
no alterations in any parameter, including liver and kid-
ney function. The control group of 42 healthy individ-
uals was an equally female-dominated group, aged
between 25 and 76 years (mean = 47.0). Blood tests
performed did not reveal abnormal renal function. Com-
pared to healthy subjects, MOH patients had higher
Zung Self-Rating Depression Scale (ZUNG-D) scores
and less prevalent alcohol consumption. No other differ-
ences were observed between the two groups. Data and
statistical comparisons are summarized in Table 1.
ELISA test
The level of L-PGDS and APOE was estimated in serum
samples collected from 69 MOH patients and 42 healthy
participants. Regarding L-PGDS, a significant increase
was observed in patients, compared to healthy individ-
uals (219.2 ng/ml vs. 188.7 ng/ml, p < 0.01). On the other
hand, the serum concentration of APOE was signifi-
cantly higher in healthy individuals (72.5 μg/ml vs.
63.9 μg/ml, p < 0.01). The level of serum VDBP was esti-
mated in a lower number of samples, i.e., in 57 MOH
patients and 31 healthy individuals. This was due to
technical problems experienced during the laboratory
practice. The control group showed significantly higher
levels of serum VDBP (343.7 μg/ml vs. 289.5 μg/ml, p <
0.01). Regarding serum APOA1, no differences were
found between 57 MOH patients and 30 healthy partici-
pants (49.8 μg/ml vs. 46.9 μg/ml, p = 0.5466). Dosages
have been performed in fewer samples, due to technical
laboratory biases. According to the prevalent acute head-
ache medication used, the concentration of serum pro-
teins was relatively stable. Data regarding the serum
concentrations of proteins are summarized in Table 2
and Table 3, as well as better displayed in Fig. 1.
Cutaneous pain thresholds
According to the absence of any significant difference
between right and left sides and the three trigeminal
branches, CPTs are presented as an overall average.
Compared to healthy participants, mean CPT values in
the three tested areas (temples, cheekbone and chin)
were significantly lower in MOH patients (46.4 g vs.
96.0 g, p < 0.01). No statistical differences were found be-
tween males and females. Data and statistical compari-
sons are described in Table 2. When the mean CPTs
values are compared with the serum concentration of
the serum proteins, no relationship is detectable for L-
PGDS (Spearman’s rank = − 0.001; p = 0.9921), VDBP
(Spearman’s rank = − 0.147; p = 0.4301), APOE (Spear-
man’s rank = 0.053; p = 0.6667) and APOA1 (Spearman’s
rank = 0.25769; p = 0.05296). Graphic correlations are
displayed in Fig. 2.
Discussion
The main findings of this study concern the serum differ-
ences of L-PGDS, VDBP and APOE in MOH patients,
compared to healthy individuals. These discrepancies were
not one-sided, as L-PGDS was identified at high concentra-
tions, while VDBP and APOE were deficient. Our group of
patients with MOH was nearly aligned with previous case
studies [27], confirming to have a higher prevalence of CA
than healthy individuals [12, 28]. Of note, the intake of opi-
oids and drugs containing barbiturates was lower; this
might be due to population differences [29] or to the study
selection criteria, which excluded patients with other pain-
ful syndromes and comorbidities. These assumptions were
ideal to correlate the serum concentration of L-PGDS,
Table 1 Demographic, clinical and laboratory data of MOH
patients and healthy individuals
MOH patients (n = 69) Controls
(n = 42)
Age, years 50.2 ± 9.2 47.0 ± 13.8
Sex, female 90% 88%
BMI, kg/m2 23.7 ± 4.5 23.7 ± 3.8
Coffee 84% 88%
Alcohol 22%* 76%
Cigarettes 9% 12%
SBP, mmHg 125.9 ± 12.4 122.1 ± 13.0
DBP, mmHg 79.3 ± 8.2 76.8 ± 8.5
DDI 1.8 ± 2.1 –
CHR 12.1 ± 10.3 –
ZUNG-D 44.3 ± 9.5** 32.3 ± 7.7
LDQ 12.1 ± 7.4 –
Creatinine, mg/dl 0.76 ± 0.12 0.79 ± 0.12
eGFR > 60ml/min > 60 ml/min
Urea nitrogen, mg/dl 29.4 ± 7.4 29.6 ± 8.5
Data are expressed as mean ± SD, or in percentage
BMI Body Mass Index; SBP systolic blood pressure; DBP diastolic blood
pressure; DDI daily drug doses; CHR years of chronification; ZUNG-D Zung Self-
Rating Depression Scale; LDQ Leeds Dependence Questionnaire; eGFR
estimated Glomerular Filtration Rate (CKD-EPI Formula)
Statistical significance was evaluated using χ2 test (*p < 0.01) or independent t
test (**p < 0.01). Coffee, alcohol and cigarettes users are expressed as a
percentage of occasional and daily users
Table 2 CPT values and serum proteins levels in healthy
individuals and MOH patients
Controls MOH patients P-value
Mean CPT (g) 96.0 ± 41.0 46.4 ± 27.7 < 0.00001**
L-PGDS (ng/ml) 188.7 ± 39.2 219.2 ± 58.2 0.0038**
VDBP (μg/ml) 343.7 ± 95.3 289.5 ± 88.7 0.0058**
APOE (μg/ml) 72.5 ± 17.3 63.9 ± 13.3 0.0042**
APOA1 (μg/ml) 46.9 ± 17.5 49.8 ± 23.7 0.546NS
CPT values and serum protein concentrations are expressed as mean ±
standard deviation (SD).Independent t test (patients vs. controls): statistical
significance **: p < 0.01, NS: not significant
Pellesi et al. BMC Neurology          (2019) 19:239 Page 4 of 9
VDBP and APOE to the pain thresholds measured on the
skin of the face. However, none of these proteins (including
APOA1) showed any relationship with CPTs.L-PGDS was
already found at unusually high concentrations in urine of
MOH patients [13, 14]. The enzyme is highly expressed in
leptomeninges [30] and is physiologically eliminated via the
kidney. It is of interest for headaches and migraine, as it
synthesizes PGD2, a strong vasodilator of the human mid-
dle cerebral artery [25], as well as a stimulus for the release
of calcitonin gene-related peptide (CGRP) from trigeminal
neurons [31]. Alterations in concentration of L-PGDS have
also been discussed in other neurological diseases, including
cerebral infarction, multiple sclerosis and schizophrenia
[32, 33]. Anyway, its high serum concentration remains un-
explained, did not exhibiting any correlation with CA. An-
other likely explanation behind its high concentration is
related to the frequent intake of pain relievers. The com-
mon and prolonged assumption of acute headache medica-
tions is not uniquely associated with worsening headache,
but also to stomach bleeding, liver and kidney damage.
NSAIDs use was associated with a 3-fold greater risk for
acute renal failure compared with non-NSAIDs use; this
risk was dose-dependent and increased with long-term use
[34]. About triptans, their potential kidney injury is less
known, although some cases of renal infarction have been
reported after prolonged use [35]. By adding that L-PGDS
accumulates in the serum of patients with impaired renal
function, especially in dialysis patients (ca. 100-fold), and it
has been proposed in the past as a diagnostic marker for
early renal injury [36, 37], the renal impairment may be a
valid argument for its elevated levels. However, the renal
function indicators in the blood of MOH patients were not
different from those of healthy volunteers.
Serum concentrations of VDBP and APOE were
higher in healthy individuals. VDBP is primarily a carrier
and transporter of vitamin D in the circulation. It also is
a component of the extracellular actin-scavenger system,
comprising gelsolin; specifically, VDBP binds and facili-
tates clearance of monomeric actin, released upon injury
[38]. Furthermore, VDBP works as a macrophage-
activating factor (MAF), initiating macrophage activity
[39]. The current result contradicts the findings in rats,
where the serum level of VDBP was elevated up to 5
weeks, after the chronic constriction injury of the sciatic
nerve [26]. However, this agrees with other human stud-
ies which investigated its role in chronic painful condi-
tions. With a methodological approach like the one we
adopted, serum VDBP was identified among the down-
regulated spots in carpal tunnel syndrome patients, com-
pared to healthy individuals [40]. Moreover, a Japanese
family study identified a possible dysfunction of VDBP
in migraineurs [41]. It has been assumed that a lower
binding of the VDBP to monocyte chemoattractant
protein-1 (MCP-1), a member of the monocyte chemo-
attractant protein family, may be involved in the devel-
opment of migraine pain. Elevated CSF levels of MCP-1
were already reported in migraine patients [42] and the
chemokine can also trigger CGRP release [43]. Regard-
ing vitamin D, the natural ligand of VDBP, more data
are available. It has been associated with the aetiology
and persistence of painful conditions [44], and its sup-
plementation can relieve pain in most patients with a
vitamin D deficiency [45]. Interestingly, vitamin D inad-
equacy has been linked to higher doses of analgesics
among patients with chronic musculoskeletal pain [46],
In migraine patients, serum vitamin D and Vitamin D
receptor levels were found to be lower than in controls,
whereas serum VDBP levels were similar between the
two groups [47]. In this study, Vitamin D was not dosed.
In the future, interesting advancements in MOH could
concern the dosage of vitamin D and MCP-1, together
with a re-evaluation of the VDBP protein.
More concealed is the association between APOE and
pain regulation processes [48]. It transports cholesterol
into the blood and has many essential functions in the
brain, including synaptogenesis, regulating synaptic
transmission and promoting nerve regeneration after a
nerve injury [49]. Despite intriguing reasons that favour
the association between APOE and pain, few human
studies were conducted to date. In relation to headache
conditions, APOE-2 allele has been identified as a risk
factor for migraine, whereas APOE ε4 allele is positively
related to headache, including migraine and tension-type
headache [50, 51]. Yet, further research is required for
the reason behind the low serum concentration of APOE
in patients with MOH.
The study has some limitations. First, our patients
were mainly represented by women, but an evaluation of
the serum proteins in the light of the hormonal state is
lacking. And, the association between these proteins and
the overuse medication has not been studied exhaust-
ively. The association between proteins and pain might
be missing because the protein markers are possibly de-
regulated from the pain state. Presumably, such alter-
ations are not directly related to the central pain
sensitization, rather to other aspects of chronic headache
or the excessive intake of acute headache medications,
e.g. the decrease of VDBP and APOE could indicate liver
Table 3 Serum proteins levels in MOH patients, according to
the prevalent acute headache medication
Triptans NSAIDs Mixtures
L-PGDS (ng/ml) 209.4 ± 57.5 214.9 ± 53.5 266.0 ± 44.6
VDBP (μg/ml) 296.0 ± 86.0 262.3 ± 67.4 287.8 ± 124.0
APOE (μg/ml) 65.6 ± 13.2 55.6 ± 10.7 64.2 ± 14.2
APOA1 (μg/ml) 46.6 ± 20.3 60.5 ± 23.0 53.3 ± 33.3
Serum protein concentrations are expressed as mean ± standard deviation (SD)
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Fig. 1 Box plots of serum concentrations of L-PGDS, VDBP and apolipoproteins in MOH patients (white) and healthy individuals (grey)
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stress due to excessive medication intake. Anyway, the
liver function of MOH patients evaluated at the admis-
sion to the hospital were not abnormal. Alternatively,
these proteins might actually be related to some aspect
of the chronic pain condition, but CPTs might function
only as a proxy for the medication overuse. In order to
understand whether medication overuse affect the serum
proteins, it would be interesting to study how these
drugs change in the light of improvements due to medi-
cation withdrawal or prophylactic therapies. Several
biomarkers were already investigated in MOH, including
genetic polymorphisms and neuroimaging abnormalities
[52], however the exploration of serum biomarkers re-
main more attractive and desirable, having the appeal of
not be affected by the patient’s hydration status and
urine flow rate, as well as being easily measurable and
suitable for follow-up.
Conclusions
In conclusion, this study has demonstrated differences in
the concentration of distinct serum proteins between
MOH patients and healthy individuals. However, none of
them appear to be involved in facial allodynia, one of the
most distinctive aspect of MOH patients. Presumably, such
alterations are not related to the central sensitization, rather
to the excessive intake of acute headache medications. It
would now be interesting to study these markers and their
role in medication overuse, correlating their progress after
a medication withdrawal or the start of prophylaxys
therapy. In the future, it would be also of interest to explore
the levels of drugs (e.g., triptans, NSAIDs, paracetamol, …)
and correlate them with the protein markers and/or other
clinical aspects of MOH.
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